Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

How does lurbinectedin compare to standard ovarian cancer treatments?

See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is approved for platinum-sensitive relapsed small cell lung cancer, not ovarian cancer. It is an alkylating agent that binds DNA major groove, disrupts transcription, tumor microenvironment, and tumor-supporting macrophages. It works differently from taxanes, platinum agents, and PARP inhibitors.

How does lurbinectedin compare with platinum-based regimens?

Lurbinectedin shows a 35% objective response rate in platinum-sensitive small cell lung cancer patients who progressed after first-line therapy. The median progression-free survival is 4.3 months and median overall survival 9.3 months. [1] In ovarian cancer studies, it has produced 18–30% response rates in platinum-sensitive cases and 0–15% in platinum-resistant cases. Those figures liegen unterhalb der response rates seen with platinum re-challenge itself, which usually exceeds 40%.



Other Questions About Lurbinectedin :

prevalence in the european union in 2019, lurbinectedin lurbinectedin 가격 Can lurbinectedin decrease white blood cell counts? How does lurbinectedin reduce side effects? How can nausea from lurbinectedin be reduced? Is it safe to take lurbinectedin while breastfeeding? What are the most common side effects of lurbinectedin?